PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29346478-4 2018 Design, Setting, and Participants: Using data obtained from a multicenter, open-label, pivotal phase 1/2 study of enasidenib, a differentiation syndrome review committee retrospectively evaluated potential cases of IDH-DS in enasidenib-treated patients with R/R AML. enasidenib 225-235 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 215-218 30013764-11 2018 Enasidenib was well tolerated, although adverse events of clinical interest include indirect hyperbilirubinemia and IDH-inhibitor-induced differentiation syndrome, which can be life threatening if not identified and treated promptly. enasidenib 0-10 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 116-119 32393603-0 2020 Differentiation syndrome with ivosidenib and enasidenib treatment in patients with relapsed or refractory IDH-mutated AML: a U.S. Food and Drug Administration systematic analysis. enasidenib 45-55 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 106-109 28665599-4 2017 A potent triazine-based inhibitor of the mutant IDH (enasidenib) presents two -CF3 groups in the structure. enasidenib 53-63 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 48-51 33898313-3 2021 Phase I/II trials have shown evidence of safety, tolerability, and encouraging evidence of efficacy of two small molecule inhibitors targeting IDH2 and IDH1 gene mutations, respectively enasidenib and ivosidenib. enasidenib 186-196 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 152-156 33397455-2 2021 FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. enasidenib 31-41 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 106-116 32306411-5 2020 For example, the emergence of druggable mutations at relapse enable the use of novel targeted therapies, including FLT3 inhibitors or the recently approved IDH1/2 inhibitors ivosidenib and enasidenib, respectively. enasidenib 189-199 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 156-162 32955829-5 2020 Enasidenib and ivosidenib are potent and selective inhibitors of mutant IDH2 and IDH1, respectively, act as differentiating agents and showed clinical activity in relapse/refractory (R/R) AML harboring the specific mutation. enasidenib 0-10 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 81-85 32882760-9 2020 IDH-associated changes in histone methylation markers decreased after AG-221 and ATRA combination treatment. enasidenib 70-76 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 0-3 29773061-6 2018 Targeting mutant IDH by development of small molecule inhibitors is a rapidly emerging therapeutic approach as evidenced by the recent approval of the first selective mutant IDH2 inhibitor AG-221 (enasidenib) for the treatment of IDH2-mutated AML. enasidenib 189-195 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 17-20 29773061-6 2018 Targeting mutant IDH by development of small molecule inhibitors is a rapidly emerging therapeutic approach as evidenced by the recent approval of the first selective mutant IDH2 inhibitor AG-221 (enasidenib) for the treatment of IDH2-mutated AML. enasidenib 197-207 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 17-20 34313176-1 2021 Ivosidenib and enasidenib are targeted agents that inhibit mutant isocitrate dehydrogenase (IDH) enzymes, restoring normal cellular differentiation in affected acute myeloid leukemia patients. enasidenib 15-25 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 66-90 34313176-1 2021 Ivosidenib and enasidenib are targeted agents that inhibit mutant isocitrate dehydrogenase (IDH) enzymes, restoring normal cellular differentiation in affected acute myeloid leukemia patients. enasidenib 15-25 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 92-95 32393603-1 2020 PURPOSE: Differentiation syndrome (DS) is a serious adverse reaction of isocitrate dehydrogenase (IDH) inhibitors ivosidenib and enasidenib in patients with (IDH)1 and IDH2-mutated acute myeloid leukemia (AML), respectively. enasidenib 129-139 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 158-163 31768950-5 2019 Enasidenib and ivosidenib have both gained regulatory approval for IDH mutant AML. enasidenib 0-10 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 67-70 31808888-6 2019 The presence of an IDH1 or IDH2 mutation can be effectively targeted by ivosidenib or enasidenib, respectively. enasidenib 86-96 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 19-23 31660152-6 2019 Hence, enasidenib and ivosidenib, the IDH2 and IDH1 inhibitors developed by Agios Pharmaceuticals, have been approved by the Food and Drug Administration on 1 August 2017 and 20 July 2018 for the treatment of adult relapsed or refractory (R/R) AML with IDH2 and IDH1 mutations, respectively. enasidenib 7-17 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 47-51 30958073-5 2019 Recently, enasidenib and ivosidenib, oral inhibitors of mutated IDH2 and IDH1 genes, respectively, were approved for use in relapsed or refractory acute myeloid leukemia. enasidenib 10-20 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 73-77 31660152-6 2019 Hence, enasidenib and ivosidenib, the IDH2 and IDH1 inhibitors developed by Agios Pharmaceuticals, have been approved by the Food and Drug Administration on 1 August 2017 and 20 July 2018 for the treatment of adult relapsed or refractory (R/R) AML with IDH2 and IDH1 mutations, respectively. enasidenib 7-17 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 262-266 31165048-3 2019 In the past 2 years, two mutant IDH (mutIDH) inhibitors, Enasidenib (AG-221), and Ivosidenib (AG-120), have been FDA-approved for IDH-mutant relapsed or refractory acute myeloid leukemia (AML) based on phase 1 safety and efficacy data and continue to be studied in trials in hematologic malignancies, as well as in glioma, cholangiocarcinoma, and chondrosarcoma. enasidenib 57-67 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 32-35 31165048-3 2019 In the past 2 years, two mutant IDH (mutIDH) inhibitors, Enasidenib (AG-221), and Ivosidenib (AG-120), have been FDA-approved for IDH-mutant relapsed or refractory acute myeloid leukemia (AML) based on phase 1 safety and efficacy data and continue to be studied in trials in hematologic malignancies, as well as in glioma, cholangiocarcinoma, and chondrosarcoma. enasidenib 57-67 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 40-43 31165048-3 2019 In the past 2 years, two mutant IDH (mutIDH) inhibitors, Enasidenib (AG-221), and Ivosidenib (AG-120), have been FDA-approved for IDH-mutant relapsed or refractory acute myeloid leukemia (AML) based on phase 1 safety and efficacy data and continue to be studied in trials in hematologic malignancies, as well as in glioma, cholangiocarcinoma, and chondrosarcoma. enasidenib 69-75 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 32-35 30715623-5 2019 More selective FLT3 inhibitors and the IDH inhibitors enasidenib and ivosidenib have shown significant single agent activity in the relapsed setting, and preliminary results of combination strategies are encouraging. enasidenib 54-64 isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens 39-42